Decreased circulating levels of il-22 in newlydiagnosed metabolic syndrome patients

Abstract

Aim Metabolic syndrome (MetS) is characterized by abdominal obesity, dyslipidemia, low-grade inflammation, insulin resistance, and hypertension that can lead to diabetes and cardiovascular disease. IL-22 is a member of the IL-10 cytokine family that has been shown to prevent or reverse obesity-induced glucose intolerance and insulin resistance; it also affects mucosal barrier maintenance and the prevention of endotoxemia and chronic inflammation. We determine IL-22 levels in MetS patients and whether IL-22 is associated with MetS and its components.Methods In this cross-sectional study, we measured serum IL-22 in 194 patients who had been newly diagnosed with MetS; we also employed 73 control patients. We used logistic regression analyses to evaluate the association of low serum levels of IL-22 with metabolic syndrome after adjusting for potential confounders.Results Serum IL-22 concentrations were lower in subjects with MetS than in the controls. Serum IL-22 was negatively correlated with adiposity, fasting insulin, fasting glucose, C-reactive protein, triglycerides, and body mass index; it was positively correlated with HDL cholesterol. Logistic regression analysis demonstrated an independent association
between serum IL-22 and metabolic syndrome.Conclusion These data suggested that decreased IL-22 levels are associated with MetS and its components and that IL-22 may be a novel biomarker in metabolic and endocrine regulations.

Keywords

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →